4//SEC Filing
Hopfner Robert Lorne 4
Accession 0001551966-25-000007
CIK 0002044725other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:19 PM ET
Size
34.9 KB
Accession
0001551966-25-000007
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
Hopfner Robert Lorne
Director10% Owner
Transactions
- Conversion
Common Stock
2025-11-07+1,441,032→ 1,441,032 total(indirect: By NFLS Delta III Limited) - Conversion
Series B Preferred Stock
2025-11-07−2,104,740→ 0 total(indirect: By Pivotal bioVenture Partners Fund I, L.P.)→ Common Stock (267,367 underlying) - Conversion
Series C Preferred Stock
2025-11-07−313,571→ 0 total(indirect: By NFLS Delta III Limited)→ Common Stock (36,812 underlying) - Conversion
Series A Preferred Stock
2025-11-07−7,230,283→ 0 total(indirect: By Pivotal bioVenture Partners Fund I, L.P.)→ Common Stock (908,821 underlying) - Conversion
Series B Preferred Stock
2025-11-07−1,895,260→ 0 total(indirect: By NFLS Delta III Limited)→ Common Stock (240,756 underlying) - Conversion
Series C Preferred Stock
2025-11-07−313,571→ 0 total(indirect: By Pivotal bioVenture Partners Fund I, L.P.)→ Common Stock (36,812 underlying) - Conversion
Series C Preferred Stock
2025-11-07−2,508,575→ 0 total(indirect: By Pivotal bioVenture Partners Fund II, L.P.)→ Common Stock (294,502 underlying) - Conversion
Common Stock
2025-11-07+3,026→ 3,026 total(indirect: By Trust) - Conversion
Common Stock
2025-11-07+1,632,441→ 1,632,441 total(indirect: By Pivotal bioVenture Partners Fund I, L.P.) - Conversion
Series A Preferred Stock
2025-11-07−2,582,243→ 0 total(indirect: By NFLS Delta III Limited)→ Common Stock (324,578 underlying) - Conversion
Common Stock
2025-11-07+294,502→ 294,502 total(indirect: By Pivotal bioVenture Partners Fund II, L.P.) - Conversion
Series Seed Preferred Stock
2025-11-07−7,145,647→ 0 total(indirect: By NFLS Delta III Limited)→ Common Stock (838,886 underlying) - Conversion
Series Seed Preferred Stock
2025-11-07−25,790→ 0 total(indirect: By Trust)→ Common Stock (3,026 underlying) - Conversion
Series Seed Preferred Stock
2025-11-07−3,572,816→ 0 total(indirect: By Pivotal bioVenture Partners Fund I, L.P.)→ Common Stock (419,441 underlying)
Footnotes (8)
- [F1]Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.
- [F2]The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
- [F3]Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
- [F4]Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
- [F5]Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
- [F6]Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
- [F7]Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
- [F8]Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Documents
Issuer
Evommune, Inc.
CIK 0002044725
Entity typeother
Related Parties
1- filerCIK 0001551966
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 4:19 PM ET
- Size
- 34.9 KB